Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Medtronic
Colorcon
Moodys
McKinsey

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,603,521

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,603,521
Title:Formulations of histone deacetylase inhibitor and uses thereof
Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
Inventor(s): Loury; David J. (San Jose, CA), Buggy; Joseph J. (Mountain View, CA), Mody; Tarak D. (Sunnyvale, CA), Verner; Erik J. (Belmont, CA), Purro; Norbert (Los Gatos, CA), Balasubramanian; Sriram (San Carlos, CA)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:12/761,588
Patent Claims:1. A method of treating cancer in a human, comprising: orally administering a first dose of Compound 1, and orally administering a second dose of Compound 1 about 4 to about 6 hours after the first dose ##STR00005## wherein a plasma concentration of Compound 1 which is effective for treating cancer is maintained for at least 6 consecutive hours.

2. The method of claim 1, wherein the effective plasma concentration of Compound 1 is about 0.2 uM.

3. The method of claim 1, wherein AUC.sub.0-4h of Compound 1 is about 0.272.+-.0.051 .mu.Mh.

4. The method of claim 1, comprising orally administering a third dose of Compound 1, wherein the first dose, the second dose and the third dose are each administered 4 to 6 hours apart.

5. The method of claim 1, wherein the daily dose of Compound 1 is 2 mg/kg.

6. The method of claim 1, wherein the daily dose of is about 10 mg to about 300 mg.

7. The method of claim 1, wherein the cancer is a hematological cancer, solid tumor or a sarcoma.

8. The method of claim 1, wherein the cancer is selected from: breast cancer, colon cancer, colorectal carcinomas, non-small cell lung cancer, small-cell lung cancer, liver cancer, ovarian cancer, prostate cancer, uterine cervix cancer, urinary bladder cancer, gall bladder carcinoma, gastric carcinoma, esophageal cancer, gastrointestinal stromal tumor, pancreatic cancer, germ cell tumors, mast cell tumors, neuroblastoma, retinoblastoma, mesothelioma, mastocytosis, testicular cancers, glioblastomas, astrocytomas, sarcoma, osteosarcoma, B cell lymphoma, T cell lymphoma, NK cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, basal cell carcinoma, skin cancer, myeloma, leukemia, acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome, chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML).

9. The method of claim 1, wherein the cancer is selected from: breast cancer, colon cancer, colorectal carcinomas, non-small cell lung cancer, liver cancer, ovarian cancer, uterine cervix cancer, gastric carcinoma, pancreatic cancer, glioblastomas, B cell lymphoma, T cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myeloma, myelodysplastic syndrome (MDS).

10. The method of claim 1, further comprising administering to the human at least one additional therapy selected from anti-cancer agents, anti-emetic agents, radiation therapy, or combinations thereof.

11. The method of claim 1, further comprising administering to the human at least one additional therapeutic agent selected from: DNA-damaging agents; topoisomerase I or II inhibitors; alkylating agents; PARP inhibitors; proteasome inhibitors; RNA/DNA antimetabolites; antimitotics; immunomodulatory agents; antiangiogenics; aromatase inhibitors; hormone-modulating agents; apoptosis inducing agents; kinase inhibitors; monoclonal antibodies; or combinations thereof.

12. The method of claim 1, further comprising administering to the human at least one additional therapeutic agent selected from: abarelix; ABT-888; aldesleukin; aldesleukin; alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine anastrozole; arsenic trioxide; asparaginase; azacitidine; AZD-2281; arsenic trioxide; bendamustine; bevacizumab; bexarotene; bleomycin; bortezomib; BSI-201; busulfan; busulfan; calusterone; capecitabine; carboplatin; carfilzomib; carmustine; carmustine; celecoxib; cetuximab; chlorambucil; cisplatin; cladribine; clofarabine; cyclophosphamide; cytarabine; cytarabine liposomal; dacarbazine; dactinomycin; darbepoetin alfa; dasatinib; daunorubicin liposomal; daunorubicin; decitabine; denileukin; dexrazoxane; docetaxel; doxorubicin; doxorubicin liposomal; dromostanolone propionate; epirubicin; epoetin alfa; erlotinib; estramustine; etoposide phosphate; etoposide; exemestane; filgrastim; floxuridine; fludarabine; fluorouracil; fulvestrant; gefitinib; gemcitabine; gemtuzumab ozogamicin; goserelin acetate; histrelin acetate; hydroxyurea; Ibritumomab tiuxetan; idarubicin; ifosfamide; imatinib mesylate; interferon alfa 2a; Interferon alfa-2b; irinotecan; lenalidomide; letrozole; leucovorin; leuprolide Acetate; levamisole; lomustine; meclorethamine; megestrol acetate; melphalan; mercaptopurine; methotrexate; methoxsalen; mitomycin C; mitomycin C; mitotane; mitoxantrone; nandrolone phenpropionate; nelarabine; NPI-0052; nofetumomab; oprelvekin; oxaliplatin; paclitaxel; paclitaxel protein-bound particles; palifermin; pamidronate; panitumumab; pegademase; pegaspargase; pegfilgrastim; pemetrexed disodium; pentostatin; pipobroman; plicamycin, mithramycin; porfimer sodium; procarbazine; quinacrine; RAD001; rasburicase; rituximab; sargramostim; Sargramostim; sorafenib; streptozocin; sunitinib malate; tamoxifen; temozolomide; teniposide; testolactone; thalidomide; thioguanine; thiotepa; topotecan; toremifene; tositumomab; tositumomab/I-131 tositumomab; trastuzumab; tretinoin; uracil Mustard; valrubicin; vinblastine; vincristine; vinorelbine;vorinostat; zoledronate; zoledronic acid; vandetanib; lapatinib; nilotinib; axitinib; or combinations thereof.

13. The method of claim 1, further comprising administering to the human at least one additional therapeutic agent selected from: azacitidine; bendamustine; bevacizumab; bleomycin; bortezomib; carboplatin; chlorambucil; cisplatin; cyclophosphamide; cytarabine; dacarbazine; darbepoetin alfa; daunorubicin liposomal; daunorubicin; decitabine; docetaxel; doxorubicin; doxorubicin liposomal; epirubicin; epoetin alfa; erlotinib; etoposide; fludarabine; fluorouracil; gemcitabine; Ibritumomab tiuxetan; irinotecan; lenalidomide; leucovorin; melphalan; methotrexate; oxaliplatin; paclitaxel; paclitaxel protein-bound particles; pemetrexed disodium; pentostatin; RAD001; rituximab; sorafenib; sunitinib malate; tamoxifen; temozolomide; topotecan; tositumomab; tositumomab/I-131 tositumomab; trastuzumab; vincristine; vinorelbine; or combinations thereof.

Details for Patent 8,603,521

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Pharmacyclics, Inc. (Sunnyvale, CA) 2029-04-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Pharmacyclics, Inc. (Sunnyvale, CA) 2029-04-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Pharmacyclics, Inc. (Sunnyvale, CA) 2029-04-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Pharmacyclics, Inc. (Sunnyvale, CA) 2029-04-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Baxter
McKinsey
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.